Nivolumab for the Treatment of mRCC

Clinical Pearls

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.

• Nivolumab’s novel mechanism of action makes it potentially useful for RCC.
• Nivolumab looks promising in this space because of its durability of responses, impact on survival, and favorable safety profile.
• Nivolumab is being compared with everolimus in patients with clear cell mRCC. OS is the primary endpoint.